Free 2 day AUS and US shipping for orders above $200 • Register for an account to receive 20% off

Ipamorelin 10mg

Ipamorelin 10mg

$60.00

Ipamorelin 10mg is a high-purity, research-grade peptide known for its selective action as a growth hormone secretagogue (GHS). It is widely studied for its role in stimulating GH release through the ghrelin receptor pathway while maintaining high receptor specificity. Ipamorelin is a synthetic pentapeptide designed to mimic the natural hormone ghrelin by binding to growth hormone secretagogue receptors (GHSR) in the pituitary gland. Unlike earlier GHRP compounds, research shows that Ipamorelin selectively stimulates growth hormone (GH) secretion without significantly affecting cortisol or prolactin levels. This precision and receptor selectivity make it a key compound in endocrine and metabolic pathway research, particularly in studies focused on GH regulation, recovery mechanisms, and age-related hormone dynamics.

This material is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.

In Stock

Data Sheet

Molecular Formula C₃₈H₄₉N₉O₅
CAS Number 170851-70-4
Molar Mass 711.85 g/mol
Amino Acid Sequence Aib-His-D-2-Nal-D-Phe-Lys-NHâ‚‚
PubChem CID 9831659
Primary Research Area Selective Growth Hormone Secretagogue
Ghrelin/GHS Receptor Agonist
Longitudinal Bone Growth
Gastrointestinal Motility Disorders (Postoperative Ileus)
Muscle Growth
Metabolism
Bone Density
Purity >99%
Research Summary Description
The benefits of Ipamorelin growth hormone Summary: This article states that Ipamorelin increases growth hormone levels by stimulating the hypothalamus, leading to increased muscle mass and strength, as well as fat loss due to increased metabolism and lipolysis. It also notes benefits such as improved workouts and recovery, reduced body fat, increased energy, and deeper sleep.

Citation: NYMD Center. (n.d.). The Benefits of Ipamorelin Growth Hormone.
Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats Summary: This study demonstrated that Ipamorelin dose-dependently increased the longitudinal bone growth rate (LGR) and body weight gain in adult female rats.

Citation: Johansen, P. B., Nowak, J., Skjaerbaek, C., Flyvbjerg, A., Andreassen, T. T., Wilken, M., & Orskov, H. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research, 9(2), 106-113.
Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus Summary: This study showed that Ipamorelin accelerated gastric emptying and intestinal transit in a rodent model of postoperative ileus (POI). This effect is mediated by its action on ghrelin receptors located on cholinergic neurons in the gut.

Citation: Beck, D. E., Sweeney, W. B., & McCarter, M. D. (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527-1534.
Ipamorelin, the first selective growth hormone secretagogue Summary: This study identified Ipamorelin as the first selective growth hormone secretagogue. This selectivity means it stimulates GH release without significantly affecting other hormones like adrenocorticotropic hormone (ACTH) and cortisol, unlike some other GH-releasing peptides.

Citation: Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561.
Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients Summary: This human clinical trial investigated the efficacy of Ipamorelin in managing postoperative ileus (POI), a common complication after bowel surgery, by leveraging its ghrelin mimetic properties to improve gastrointestinal motility. Patients undergoing bowel resection received either Ipamorelin or placebo. While the study did not reach statistical significance for its primary endpoints (time to first tolerated meal and first bowel movement) when comparing the entire Ipamorelin group to placebo, some data suggested a trend towards shorter times to return of gastrointestinal function, particularly in patients undergoing open laparotomy.

Citation:
Beck, D. E., Sweeney, W. B., & McCarter, M. D. (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527–1534.
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers Summary: This study focused on the pharmacokinetic and pharmacodynamic properties of Ipamorelin in healthy human volunteers. It characterized how Ipamorelin is absorbed, distributed, metabolized, and excreted in the body, and how these processes relate to its effect on GH release. The study found that Ipamorelin significantly increases plasma GH levels in humans, with peak concentrations typically occurring within an hour of administration, and that it has a relatively short half-life (approximately 2 hours).

Citation:
Gobburu, J., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1324–1330.

The benefits of Ipamorelin growth hormone

Summary: This article states that Ipamorelin increases growth hormone levels by stimulating the hypothalamus, leading to increased muscle mass and strength, as well as fat loss due to increased metabolism and lipolysis. It also notes benefits such as improved workouts and recovery, reduced body fat, increased energy, and deeper sleep.

Citation: NYMD Center. (n.d.). The Benefits of Ipamorelin Growth Hormone.

Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats

Summary: This study demonstrated that Ipamorelin dose-dependently increased the longitudinal bone growth rate (LGR) and body weight gain in adult female rats.

Citation: Johansen, P. B., Nowak, J., Skjaerbaek, C., Flyvbjerg, A., Andreassen, T. T., Wilken, M., & Orskov, H. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research, 9(2), 106-113.

Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus

Summary: This study showed that Ipamorelin accelerated gastric emptying and intestinal transit in a rodent model of postoperative ileus (POI). This effect is mediated by its action on ghrelin receptors located on cholinergic neurons in the gut.

Citation: Beck, D. E., Sweeney, W. B., & McCarter, M. D. (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527-1534.

Ipamorelin, the first selective growth hormone secretagogue

Summary: This study identified Ipamorelin as the first selective growth hormone secretagogue. This selectivity means it stimulates GH release without significantly affecting other hormones like adrenocorticotropic hormone (ACTH) and cortisol, unlike some other GH-releasing peptides.

Citation: Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561.

Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients

Summary: This human clinical trial investigated the efficacy of Ipamorelin in managing postoperative ileus (POI), a common complication after bowel surgery, by leveraging its ghrelin mimetic properties to improve gastrointestinal motility. Patients undergoing bowel resection received either Ipamorelin or placebo. While the study did not reach statistical significance for its primary endpoints (time to first tolerated meal and first bowel movement) when comparing the entire Ipamorelin group to placebo, some data suggested a trend towards shorter times to return of gastrointestinal function, particularly in patients undergoing open laparotomy.

Citation:
Beck, D. E., Sweeney, W. B., & McCarter, M. D. (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527–1534.

Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers

Summary: This study focused on the pharmacokinetic and pharmacodynamic properties of Ipamorelin in healthy human volunteers. It characterized how Ipamorelin is absorbed, distributed, metabolized, and excreted in the body, and how these processes relate to its effect on GH release. The study found that Ipamorelin significantly increases plasma GH levels in humans, with peak concentrations typically occurring within an hour of administration, and that it has a relatively short half-life (approximately 2 hours).

Citation:
Gobburu, J., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1324–1330.

All content and product details on this website are provided solely for informational and educational purposes.

View Cart (0 items)

Your cart is empty

Start Shopping
20% OFF